{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:46:38Z","timestamp":1785818798037,"version":"3.56.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Integrins are involved in extracellular matrix interactions and tumor progression, but the comparative clinical relevance of \u03b1v\u03b23, \u03b1v\u03b25, and \u03b1v\u03b26 in osteosarcoma remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort included 193 patients with histologically confirmed osteosarcoma and available formalin-fixed, paraffin-embedded tumor specimens, evaluable immunohistochemical staining, and follow-up data. Corresponding hematoxylin and eosin-stained sections were reviewed to identify viable osteosarcoma-containing regions. H-score assessment for \u03b1v\u03b23, \u03b1v\u03b25, and \u03b1v\u03b26 was restricted to morphologically identifiable viable osteosarcoma cells, while non-tumoral staining was excluded. Two observers blinded to clinical data independently evaluated staining intensity and the percentage of positive tumor cells. Median H-scores were used for Kaplan\u2013Meier curve visualization, whereas H-scores were modeled continuously in Cox regression analyses. Event-free survival (EFS) and metastasis-free survival (MFS) were analyzed using Kaplan\u2013Meier and Cox models adjusted for age, sex, and tumor necrosis rate. MFS analyses included 183 patients without metastatic disease at baseline. Exploratory combined-expression analyses were also performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All three integrins showed heterogeneous expression in osteosarcoma tissues. \u03b1v\u03b23 expression was significantly higher in patients who developed metastatic events during follow-up, whereas \u03b1v\u03b25 and \u03b1v\u03b26 were not associated with metastatic events. High \u03b1v\u03b23 expression was associated with poorer EFS (p = 0.003) and MFS (p = 0.001). In multivariable models, continuous \u03b1v\u03b23 H-score remained associated with poorer EFS (HR, 1.011; 95% CI, 1.005\u20131.017; p &amp;lt; 0.001) and MFS (HR, 1.012; 95% CI, 1.006\u20131.019; p &amp;lt; 0.001). \u03b1v\u03b25 and \u03b1v\u03b26 were not significantly associated with survival, and combined-expression analyses did not provide clear additional prognostic discrimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among the three \u03b1v-containing integrins examined, \u03b1v\u03b23 showed the most consistent association with metastatic events during follow-up and poorer EFS and MFS. Its long-term prognostic relevance and clinical applicability require validation in larger independent cohorts with longer follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1888679","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:27:15Z","timestamp":1785817635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative clinical and prognostic significance of integrin \u03b1v\u03b23, \u03b1v\u03b25, and \u03b1v\u03b26 in osteosarcoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Chaoqun","family":"You","sequence":"first","affiliation":[{"name":"Musculoskeletal Tumor Center, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Musculoskeletal Tumor","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanwei","family":"Zeng","sequence":"additional","affiliation":[{"name":"Musculoskeletal Tumor Center, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Musculoskeletal Tumor","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Musculoskeletal Tumor Center, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Musculoskeletal Tumor","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuhui","family":"Xu","sequence":"additional","affiliation":[{"name":"Musculoskeletal Tumor Center, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Musculoskeletal Tumor","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ren","sequence":"additional","affiliation":[{"name":"Musculoskeletal Tumor Center, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Musculoskeletal Tumor","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xie","sequence":"additional","affiliation":[{"name":"Musculoskeletal Tumor Center, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Musculoskeletal Tumor","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Song","sequence":"additional","affiliation":[{"name":"Musculoskeletal Tumor Center, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Musculoskeletal Tumor","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Tang","sequence":"additional","affiliation":[{"name":"Musculoskeletal Tumor Center, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Musculoskeletal Tumor","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[{"name":"Musculoskeletal Tumor Center, Peking University People\u2019s Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Musculoskeletal Tumor","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0046-y","article-title":"Review of osteosarcoma and current management","volume":"3","author":"Durfee","year":"2016","journal-title":"Rheumatol Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12938-021-00860-0","article-title":"Osteosarcoma: a review of current and future therapeutic approaches","volume":"20","author":"Zhao","year":"2021","journal-title":"BioMed Eng Online"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.780264","article-title":"Osteosarcoma and metastasis","volume":"11","author":"Sheng","year":"2021","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-018-9763-8","article-title":"From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma","volume":"37","author":"Dean","year":"2018","journal-title":"Cancer Metastasis Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/medsci7020028","article-title":"Identification of prognostic and predictive osteosarcoma biomarkers","volume":"7","author":"Zamborsky","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41698-024-00794-5","article-title":"Integrins identified as potential prognostic markers in osteosarcoma through multi-omics and multi-dataset analysis","volume":"9","author":"Cui","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0038-z","article-title":"Every step of the way: integrins in cancer progression and metastasis","volume":"18","author":"Hamidi","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.3390\/ijms26073143","article-title":"Integrins in cancer drug resistance: molecular mechanisms and clinical implications","volume":"26","author":"Kariya","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.579068","article-title":"The biological functions and clinical applications of integrins in cancers","volume":"11","author":"Su","year":"2020","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006478","article-title":"\u03b1V integrins in angiogenesis and cancer","volume":"1","author":"Weis","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10461","article-title":"Targeting \u03b1v\u03b23 and \u03b1v\u03b25 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model","volume":"7","author":"Gvozdenovic","year":"2016","journal-title":"Oncotarget"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2174\/138945009788680374","article-title":"Defining the role of integrin alphavbeta6 in cancer","volume":"10","author":"Bandyopadhyay","year":"2009","journal-title":"Curr Drug Targets"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.12.005","article-title":"Nephroblastoma overexpressed gene (NOV) enhances cell motility and COX-2 upregulation of human osteosarcoma involves \u03b1v\u03b25 integrin, ILK and AP-1-dependent pathways","volume":"81","author":"Huang","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13046-020-01685-w","article-title":"The role of extracelluar matrix in osteosarcoma progression and metastasis","volume":"39","author":"Cui","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41420-023-01417-x","article-title":"The role of integrin family in bone metabolism and tumor bone metastasis","volume":"9","author":"Mao","year":"2023","journal-title":"Cell Death Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1186\/s12967-025-06906-4","article-title":"The integrin \u03b12-osteoclast axis: a key driver of bone destruction and therapeutic target in osteosarcoma","volume":"23","author":"Wei","year":"2025","journal-title":"J Transl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.98.4.1853","article-title":"Integrin activation controls metastasis in human breast cancer","volume":"98","author":"Felding-Habermann","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-005-0599-6","article-title":"Association of \u03b1v\u03b23 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells","volume":"21","author":"Duan","year":"2005","journal-title":"Clin Exp Metastasis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/0008-5472.can-23-1307","article-title":"Osteosarcoma cells secrete CXCL14 that activates integrin \u03b111\u03b21 on fibroblasts to form a lung metastatic niche","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1888679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:27:15Z","timestamp":1785817635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1888679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1888679"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1888679","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1888679"}}